Skip to main content

Table 5 Adverse events and serious (grade 3 or 4) adverse events reported

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

  MSKCC
Treatment nal-IRI + 5-FU/LV
Patients 56
toxicities any grade (%) grade 3/4 (%)
Nausea 33 (59) 2 (4)
Vomiting 18 (32) 2 (4)
Diarrhea 35 (63) 1 (2)
Fatigue 45 (80) 1 (2)
Anorexia 32 (57) 0 (0)
Neutropenia 16 (29) 1 (2)
Anemia 50 (89) 10 (18)